

01-31-08

Handwritten initials



Express Mail No. EV 811 561 502 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bhagwat et al.

Confirmation No.: 9314

Application No.: 10/718,185

Group Art Unit: 1617

Filed: November 19, 2003

Examiner: Claytor, Deirdre Renee

For: INDAZOLE COMPOUNDS,
COMPOSITIONS THEREOF AND
METHODS OF TREATMENT
THEREWITH

Attorney Docket No.: 10624-143-999
(CAM: 700755-999142)

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

01/31/2008 SDENB083 00000037 503013 10718185
01 FC:1814 130.00 DA

Sir:

Signal Pharmaceuticals, LLC is the assignee of the entire right, title and interest in and to U.S. Patent No. 7,220,771 (the "'771 patent") by virtue of assignments from the inventors to Signal Pharmaceuticals, Inc. recorded in the United States Patent and Trademark Office ("USPTO") on March 15, 2002 at Reel 012680 / Frame 0489 and March 18, 2002 at Reel 012692 / Frame 0030 in connection with U.S. Patent No. 6,897,231, of which the '771 patent is a continuation, and a conversion from "Inc." to "LLC" recorded in the USPTO on January 14, 2005 at Reel 016152 / Frame 0692.

Signal Pharmaceuticals, LLC is also the assignee of the entire right, title and interest in and to the above-identified application by virtue of an assignment from the inventors to Signal Pharmaceuticals, LLC recorded in the United States Patent and Trademark Office USPTO on August 23, 2004 at Reel 015716 / Frame 0399.

Signal Pharmaceuticals, LLC hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the '771 patent, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the '771 patent.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration of the full statutory term of the '771 patent in the event that the '771 patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

A fee of \$ 130.00 is believed due under 37 C.F.R. 1.20(d) for the submission of this terminal disclaimer. Please charge this, and any other required fees, to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Date January 29, 2008

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203
By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)
JONES DAY
222 East 41st Street
New York, New York 10017
(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12265 El Camino Real, Suite 200
San Diego, California 92130
(858) 314-1130